Clinical Trial Update: Dose-confirmatory Bridging Study in Total Hip Replacement [Phase 3]

View source ↗

Summary

Phase 3 dose-confirmatory bridging trial in total hip replacement sponsored by Bayer has completed, focusing on prevention of venous thromboembolism.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Venous Thromboembolism

Snippet

Sponsor: Bayer | Conditions: Venous Thromboembolism | Phase 3 | Status: COMPLETED